0
0
A panel of advisers to the US Centers for Disease Control and Prevention (CDC) has voted in favor of recommending Merck & Co.’s new antibody drug designed to protect infants from respiratory syncytial virus (RSV). The decision marks a significant milestone for Merck, a leading pharmaceutical company with a long history of vaccine and therapeutic development.
RSV is a common respiratory virus that can cause severe illness in young children, particularly infants. The endorsement from the CDC panel is expected to pave the way for broader use of Merck’s antibody treatment as part of routine preventive care for infants during RSV season.
Merck, officially founded in 1891 and headquartered in New Jersey, has been at the forefront of vaccine and drug innovation for over a century. The company operates globally under the names Merck & Co. in the US and Merck Sharp & Dohme outside the US and Canada. Its pharmaceutical segment, which includes research and commercialization of human health products, has produced several blockbuster drugs and vaccines over the years.
The CDC panel’s recommendation is a crucial step before the agency issues formal guidance for healthcare providers. If adopted, Merck’s RSV antibody could become a key tool in reducing RSV-related hospitalizations and complications among infants nationwide.
About Merck & Co.
Merck & Co. is a multinational pharmaceutical and healthcare company with a market capitalization of nearly $196 billion as of May 2025. The company is known for its robust research pipeline and commitment to advancing treatments in oncology, immunology, virology, and other medical fields. Merck’s animal health division also plays a significant role in veterinary medicine.
Disclaimer
This article is based on publicly available information as of June 27, 2025, including recent news reports and company data. It is intended for informational purposes only and does not constitute medical or investment advice. For medical guidance, consult a qualified healthcare professional. For investment decisions, please consult a licensed financial advisor.
